Reflector welcomes the signs of EU agreement on encouraging the development of rare disease treatments.
Reflector wonders whether the UK government's business supremo can work his magic on European pharma and biotech.
Reflector casts doubt on European pharma's vision for further communication between the industry and its patients.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva